Φορτώνει......
Immunotherapy for metastatic prostate cancer
Chemotherapy with docetaxel is the standard treatment for men with metastatic prostate cancer, and results in statistically significant improvements in survival, as well as in quality of life. However, the response rate to single-agent docetaxel is approximately 40% to 45%, emphasizing a need for al...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Urol Oncol |
|---|---|
| Κύριος συγγραφέας: | |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2007
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4886229/ https://ncbi.nlm.nih.gov/pubmed/18593624 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2007.03.029 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|